Themes ETFs Surpasses $100 Million in Assets Under Management in their Thematic & Sector-Based Product Suite
GREENWICH, Conn., June 10, 2025 (GLOBE NEWSWIRE) -- Themes ETFs, a rapidly growing issuer of thematic and leveraged single-stock ETFs, today announced it has surpassed $100 million in assets under management (AUM) in their suite of thematic and sector-based products. The milestone marks a significant moment for the firm, which has quickly established itself as a nimble, forward-thinking and low-cost player in the ETF landscape.
Launched in December 2023, Themes ETFs offers a curated suite of 18 products that allow investors to express high-conviction views on market-moving themes and iconic companies across commodities, fundamentals, and thematics. The firm's accelerated growth reflects strong investor interest in targeted exposure, amplified strategies, and tools designed for today's fast-evolving market.
'We've gone from a start up to 100 million plus in short order,' said Paul Marino, Chief Revenue Officer of Themes ETFs. 'This is proof that the product set resonates and that low fees make a difference with investors. We have every indication that growth will continue to accelerate from this important milestone.'
In addition to Themes ETFs' thematic and sector-based funds, Leverage Shares by Themes platform currently features 16 leveraged and inverse ETFs tied to individual stocks across sectors such as defense, technology, airlines, and healthcare. Recent fund launches include exposure to names like Raytheon (RTX), Broadcom (AVGO), and Palantir (PLTR)—companies central to key U.S. economic and geopolitical narratives.
The inclusion of Leverage Shares by Themes' AUM brings the firm's total AUM to $184,214,829M.
As Themes ETFs continues to build momentum, the firm remains focused on expanding its lineup and deepening relationships with traders, advisors, and institutions seeking new ways to engage with market trends.
For more information about these ETFs and other products offered by Leverage Shares by Themes, please visit www.leverageshares.com/us.
For media inquiries, please contact:
Arielle Shternfeld, Director, Communications and Advisor RelationsEmail: ashternfeld@themesetfs.comPhone: +1 203-405-8665
About Themes ETFs:
Themes ETFs was established by the Co-Founders as a direct affiliate of Leverage Shares in 2023. Themes Management Company LLC serves as an adviser to the Themes ETFs Trust. Themes ETFs seeks to provide investors with targeted exposure to specific segments of the market via its low-cost ETFs. For more information, visit www.themesetfs.com.
About Leverage Shares:
Leverage Shares is the pioneer and largest issuer of single stock ETPs in Europe.1 The company was launched in 2017 by CEO Jose Gonzalez-Navarro, COO Dobromir Kamburov and General Counsel Tracy Grant (the 'Co-Founders') and has 160+ ETPs offering both leveraged and unleveraged exposure to single stocks, ETFs and commodities across various exchanges in Europe. Named Best ETP Provider in 2021 in the International Financial Awards. For more information, please visit www.leverageshares.com
1Source: Leverage Shares, as of 9 October 2024, by AUM and trading volumes.
Investment involves significant risk. Fund does not invest directly in the underlying stock. Investing in the Fund involves a high degree of risk. As with any investment, there is a risk that you could lose all or a portion of your investment in the Fund.
AMDG, ARMG, ASMG, COIG, NVDG, TSLG, and TSMG are designed to provide investors with amplified returns (up and down) on innovative companies in the technology sector.
The Funds are not suitable for all investors. The Funds are designed to be utilized only by knowledgeable investors who understand the potential consequences of seeking daily leveraged (2X) investment results, understand the risks associated with the use of leverage and are willing to monitor their portfolios frequently. The Funds are not intended to be used by, and is not appropriate for, investors who do not intend to actively monitor and manage their portfolios. For periods longer than a single day, the Funds will lose money if the Underlying Stock's performance is flat, and it is possible that the Funds will lose money even if the Underlying Stock's performance increases over a period longer than a single day. An investor could lose the full principal value of his/her investment within a single day.
PERFORMANCE DISCLOSURE
The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate. An investor's shares, when redeemed, may be worth more or less than their original cost; current performance may be lower or higher than the performance quoted. Returns for performance for one year and under are cumulative, not annualized. Short term performance, in particular, is not a good indication of the fund's future performance, and an investment should not be made based solely on returns. For additional information, see the fund(s) prospectus.
INVESTMENT RISKS: Investing in the Funds involves a high degree of risk. As with any investment, there is a risk that you could lose all or a portion of your investment in the Funds.
An investor should carefully consider a Fund's investment objective, risks, charges, and expenses before investing. A Fund's prospectus and summary prospectus contain this and other information about Themes ETFs. To obtain a Fund's prospectus and summary prospectus call 886-584-3637. A Fund's prospectus and summary prospectus should be read carefully before investing.
An investment in the Fund involves risk, including the possible loss of principal. The Fund is non-diversified and includes risks associated with the Fund concentrating its investments in a particular industry, sector, or geographic region which can result in increased volatility. The use of derivatives such as futures contracts and swaps are subject to market risks that may cause their price to fluctuate over time. Risks of the Fund include effects of Compounding and Market Volatility Risk, Inverse Risk, Market Risk, Counterparty Risk, Rebalancing Risk, Intra-Day Investment Risk, Daily Index Correlation Risk, Other Investment Companies (including ETFs) Risk, and risks specific to the securities of the Underlying Stock and the sector in which it operates. These and other risks can be found in the prospectus.
Themes Management Company LLC serves as an adviser to the Themes ETFs Trust. The funds are distributed by ALPS Distributors, Inc (1290 Broadway, Suite 1000, Denver, Colorado 80203). Themes ETFs are not sponsored, endorsed, issued, sold, or promoted by these entities, nor do these entities make any representations regarding the advisability of investing in the Themes ETFs. Neither ALPS Distributors, Inc, Themes Management Company LLC nor Themes ETFs are affiliated with these entities.Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Gene Therapy Collaboration and Licensing Deals Report and Directory 2025: Explore the Financials Behind 787 Gene Therapy Licensing Deals from 2016-2025
The Gene Therapy Collaboration and Licencing Deals report features 787 deals with financial terms and SEC contracts. Explore trends in R&D partnerships, commercialization strategies, and IP structures. Ideal for benchmarking deal terms, assessing opportunities, and streamlining due diligence in the gene therapy space. Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Gene Therapy Collaboration and Licensing Deals 2016-2025" report has been added to report contains a comprehensive listing of 787 gene therapy deals announced since 2016, including financial terms where available, and links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Gene Therapy Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the gene therapy deals entered into by the world's leading biopharma revised and updated, the report provides details of gene therapy deals from 2016 to report provides a detailed understanding and analysis of how and why companies enter gene therapy deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of report includes collaboration, development, research and licensing initial chapters of this report provide an orientation of gene therapy dealmaking. Chapter 1 introduces the report, while Chapter 2 provides an overview of the trends in gene therapy dealmaking since 2016. Chapter 3 offers a summary of the leading gene therapy deals since 2016, listed by headline value. Chapter 4 lists the top 25 most active companies in gene therapy dealmaking, with summaries and comprehensive listings of deals. Chapter 5 and Chapter 6 offer detailed reviews of gene therapy deals and partnering deals announced since Jan 2016, focusing on contract documents in the public domain and specific gene therapy technologies report also includes numerous tables and figures that illustrate the trends and activities in gene therapy deal making since 2016. In addition, a comprehensive deal directory is provided, organized by company A-Z, deal type, and therapeutic target. Each deal title links via Weblink to an online version of the deal record and, where available, the contract document, providing easy access to each contract document on Therapy Collaboration and Licensing Deals provides the reader with the following key benefits: Understand deal trends since 2016 Browse gene therapy collaboration and licensing deals Benchmark analysis - identify market value of transactions Financials terms - upfront, milestone, royalties Directory of deals by company A-Z, deal type and therapy area Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess suitability of your proposed deal terms for partner companies Save hundreds of hours of research time Report ScopeGene Therapy Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of gene therapy trends and structure of deals entered into by leading biopharma companies Therapy Collaboration and Licensing Deals includes: Trends in gene therapy dealmaking in the biopharma industry Directory of gene therapy deal records covering pharmaceutical and biotechnology The leading gene therapy deals by value Most active gene therapy licensing dealmakers Gene Therapy Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where contract agreements allows due diligence of: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered:Chapter 1 - IntroductionChapter 2 - Trends in gene therapy dealmaking2.1. Introduction2.2. Gene therapy deals over the years2.3. Most active gene therapy dealmakers2.4. Gene therapy deals by deal type2.5. Gene therapy deals by therapy area2.6. Gene therapy deals by industry sector2.7. Deal terms for gene therapy deals2.7.1 Gene therapy deals headline values2.7.2 Gene therapy deal upfront payments2.7.3 Gene therapy deal milestone payments2.7.4 Gene therapy royalty ratesChapter 3 - Leading gene therapy deals3.1. Introduction3.2. Top gene therapy deals by valueChapter 4 - Most active gene therapy dealmakers4.1. Introduction4.2. Most active gene therapy dealmakers4.3. Most active gene therapy deals company profilesChapter 5 - Gene therapy contracts dealmaking directory5.1. Introduction5.2. Gene therapy contracts dealmaking directoryChapter 6 - Gene therapy dealmaking by technology typeDeal directory Deal directory - Gene therapy deals by company A-Z Deal directory - Gene therapy deals by deal type Deal directory - Gene therapy deals by therapy area For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
15 minutes ago
- Yahoo
Monaco: at the Yacht Club, Blumorpho pushes maritime finance forward, 'No time to waste'
MONACO, June 12, 2025 (GLOBE NEWSWIRE) -- The ecological transition of the maritime and port sectors has reached a critical inflection point. In a high-level working session held at the Yacht Club de Monaco, innovation met finance to chart a clear course toward healthier oceans and sustainable infrastructure. The event, led by Blumorpho in partnership with the International Association of Port Cities (AIVP) and supported by the Prince Albert II of Monaco Foundation, brought together port authorities, financial institutions, corporations, and innovators to activate actionable financial mechanisms for the sustainable transformation of coastal urban ecosystems. Part of the momentum building toward the 'Blue Economy Finance Forum' and the UN Ocean Conference (UNOC), the initiative aims to accelerate the deployment of scalable, investable solutions in support of net-zero and biodiversity objectives. Opening the session, Bernard d'Alessandri, General Secretary of the Yacht Club de Monaco, stated: 'On behalf of our President, HSH Prince Albert II, we are pleased to welcome you to the Yacht Club de Monaco to address this key issue. We would like to congratulate the Blumorpho team for their initiative and leadership. On our side, and as part of our collective ambition, 'Monaco, Capital of Advanced Yachting', we are fully committed to advancing sustainable yachting through concrete actions, including the development of the SEA Index®, a tool to assess the carbon footprint of superyachts; and support for pioneering projects through the Monaco Energy Boat Challenge (1–5 July 2025). This commitment is more essential than ever, and we are proud to contribute to the dialogue on how to protect our Ocean.' The day unfolded through expert panels, collaborative workshops, and project showcases, with three core themes emerging: ports as platforms for systemic innovation, strategic capital for climate impact, and concrete, investment-ready projects. Port cities were highlighted as drivers of integrated innovation, connecting clean energy, biodiversity, mobility, and industrial transformation. Financially, new models are gaining traction, from blended finance and blue bonds to private equity and infrastructure debt. Flagship projects from Kribi, Riga, San Diego, Genoa, and Bordeaux showcased pathways that combine decarbonization, aquaculture, digital infrastructure, and inclusive growth. 'The real challenge is not only funding the transition, but designing collaborative and business models that align profitability with long-term climate and societal goals,' explained Géraldine Andrieux, CEO of Blumorpho. Featured case studies included Ineos Energy's integrated approach to carbon capture and storage, and Republic Bank's expanding role in green infrastructure across Caribbean ports and beyond. 'As key players in the globalisation of trade, port cities bear a large share of the responsibility for the climate change. But the richness of their ecosystem means that they are also home to some of the solutions,' said Bruno Delsalle, General Manager of AIVP. The session sets the stage for a shared roadmap to be presented at the AIVP World Conference Cities & Ports 2025, scheduled in New York this November. Tisha Marajh, Group Sustainability Officer at Republic Bank, concluded with a firm call to action: 'We don't have time to waste. We are among the most affected by climate change. Phased investments tailored to attract different kinds of financing can provide a more sustainable path forward. We also need systems to identify small upstream projects, manage ESG risks, and facilitate technology transfer. Sustainable finance is a market opportunity, and we, as financial institutions, are ready to engage, if the right conditions are in place, in Caribbeans and at global scale.' For more information:- A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 minutes ago
- Yahoo
Japan Baby Care Products Market Competition, Forecast & Opportunities Report 2025: Major Players in Japan's Baby Care Market Focus on Quality and Innovation
The Japan Baby Care Products Market is expanding, driven by higher per-child spending and a demand for sustainable, health-conscious products. Opportunities include leveraging e-commerce, catering to organic and culturally preferred ingredients, and aligning with government policies on nutrition and sustainability. Japanese Baby Care Products Market Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Japan Baby Care Products Market, By Region, Competition, Forecast & Opportunities, 2020-2030F" has been added to offering. The Japan Baby Care Products Market was valued at USD 8.56 Billion in 2024 and is expected to reach USD 12.06 Billion by 2030, rising at a CAGR of 5.88%. Despite a declining birth rate, the market continues to expand, driven by higher per-child spending and a shift toward sustainable and health-conscious baby products. Japanese consumers increasingly favor organic and natural items in segments such as lotions, shampoos, wipes, and diapers, reflecting heightened concerns around product safety and skin sensitivity. The demand for high-quality, safe baby care items is further supported by the country's strong appreciation for artisanal and culturally inspired ingredients. Meanwhile, the rapid expansion of e-commerce and omnichannel retail is increasing accessibility to a wider variety of baby products. In line with this, Japan's eCommerce sector is forecast to generate revenue of USD 190.53 billion by 2025. These trends underscore the market's resilience and evolving consumer preferences, shaping its trajectory through the next decade. Key Market Drivers: Government Initiative & Policies Supporting the Food Sector The Japanese government has rolled out strategic initiatives aimed at improving nutrition among families, particularly focusing on pregnant women and young children. A core part of this effort is the Measures for Achievement of Decarbonization and Resilience with Innovation (MeaDRI), targeting zero CO2 emissions in agriculture and food systems by 2050 through sustainable practices and waste reduction. These policies support healthier food systems and reinforce the broader baby care ecosystem. The Tokyo Nutrition for Growth Summit 2021 Action Plan is another key initiative, emphasizing collaborative medical and governmental education campaigns to enhance maternal nutrition and reduce underweight pregnancies. These policies, combined with measures against childhood obesity and a stable regulatory environment, are strengthening the outlook for the baby food and baby care product markets. Key Market Challenges: Declining Birth Rate A significant obstacle for Japan's baby care products market is the continued drop in birth rates. As of 2024, Japan recorded approximately 720,000 births-the lowest since records began-reflecting a 5% decline from the previous year. This demographic shift is shrinking the consumer base for baby products, prompting major companies to reconsider domestic operations. For example, Oji Holdings ceased domestic baby diaper production to pivot toward adult incontinence products, reflecting changing market priorities. Japan's aging population, with nearly 30% aged 65 or above, exacerbates the challenge by reducing the workforce and economic productivity. While government incentives for childbirth and childcare support exist, their impact has yet to reverse the downward trend, posing long-term implications for the baby care industry. Key Market Trends: Cultural Preferences for Traditional Ingredients Cultural affinity for traditional, natural ingredients strongly influences consumer preferences in Japan's baby care segment. Parents are increasingly drawn to products incorporating heritage-based, gentle ingredients such as rice bran oil for its moisturizing properties, green tea extract for its soothing benefits, and sakura (cherry blossom) extract for its symbolic and aesthetic appeal. These components not only meet the demand for skin-friendly and safe formulations but also reflect deep-rooted cultural values. As such, manufacturers are embedding these traditional elements into baby care lines to resonate with consumers seeking authenticity and quality. This trend enhances product differentiation and reinforces local identity in a competitive and globalized market. Key Market Players: Oji Holdings Corporation Morinaga Milk Industry Co., Ltd Meiji Holdings CO., Ltd Asahi Group Foods, Ltd Miki Shoko Co., Ltd The Procter & Gamble Company Kimberly-Clark Corporation Kenvue Brands Unicharm Corporation Himalaya Wellness Company Report Scope: In this report, the Japan Baby Care Products Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: Japan Baby Care Products Market, By Product Type: Skin Care Toiletries Hair Care Food & Beverages Others Japan Baby Care Products Market, By Age Group: 0-12 Months 13-24 Months 24-48 Months Japan Baby Care Products Market, By Sales Channel: Supermarkets/Hypermarkets Specialty Stores Pharmacies/Drug Stores Online Others Japan Baby Care Products Market, By Region: Hokkaido & Tohoku Chubu Chugoku Kyushu Rest of Japan Key Attributes: Report Attribute Details No. of Pages 82 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $8.56 Billion Forecasted Market Value (USD) by 2030 $12.06 Billion Compound Annual Growth Rate 5.8% Regions Covered Japan For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Japanese Baby Care Products Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
